# PPBT catalysts: PURPLE BIOTECH LTD. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/ppbt/catalysts

> PURPLE BIOTECH LTD. (PPBT) has no upcoming catalysts in this calendar. The latest recorded is the IM1240 trial start, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, half-year only, month only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for PPBT?

PURPLE BIOTECH LTD. (PPBT) has no upcoming catalysts in this calendar. The latest recorded is the IM1240 trial start, 2026. Press release filed with the SEC (EX-99): "We plan to conduct non-GLP and GLP toxicology studies, submit an Investigational New Drug application (IND) and initiate a Phase 1 study for IM1240 in 2026." [Calendar and source filings](https://sec-api.dev/companies/ppbt/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001213900-25-110379, https://www.sec.gov/Archives/edgar/data/1614744/000121390025110379/ea026563901ex99-1_purple.htm (retrieved 2026-11-12). Last confirmed 2025-11-14. Cite: https://sec-api.dev/companies/ppbt/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | PURPLE BIOTECH LTD. |
| Ticker | PPBT (Nasdaq) |
| SEC CIK | 1614744 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/ppbt |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 31, 2018 | [Consensi (amlodipine besylate; celecoxib) FDA approval](https://sec-api.dev/pdufa/amlodipine-celecoxib) | PPBT |  | completed, approved | "NDA210045 ORIG-1 (Type 4 - New Combination): submission_status AP, submission_status_date 20180531, review_priority STANDARD; sponsor_name PURPLE BIOTECH; product CONSENSI (AMLODIPINE BESYLATE; CELECOXIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210045%22)) |
| late 2024 | [PURPLE BIOTECH LTD. topline data readout](https://sec-api.dev/companies/ppbt/catalysts) | PPBT |  | scheduled | "Topline data from Phase 2 CM24 pancreatic cancer trial expected by the end of 2024" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1614744/000121390024098732/ea022135801ex99-1_purple.htm)) |
| Feb 2025 | [Erbitux® (cetuximab) trial start](https://sec-api.dev/pdufa/cetuximab) | PPBT | recurrent and/or metastatic squamous cell carcinoma of the head and neck | completed | "In February 2025, we entered into a research agreement with the University of Colorado for an investigator-initiated Phase 2 study of NT219 in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck, which was initiated in June 2025 and is expected to conclude in June 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1614744/000121390026031365/ea0281765-20f_purple.htm)) |
| 2026 | [IM1240 trial start](https://sec-api.dev/pdufa/im1240) | PPBT |  | scheduled | "We plan to conduct non-GLP and GLP toxicology studies, submit an Investigational New Drug application (IND) and initiate a Phase 1 study for IM1240 in 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1614744/000121390025110379/ea026563901ex99-1_purple.htm)) |

## Drugs

- [Consensi (amlodipine besylate; celecoxib)](https://sec-api.dev/pdufa/amlodipine-celecoxib): 
- [IM1240](https://sec-api.dev/pdufa/im1240): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/ppbt/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PPBT catalysts: PURPLE BIOTECH LTD. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/ppbt/catalysts

```bibtex
@misc{secapidev_companies_ppbt_catalysts_20261116,
  title        = {PPBT catalysts: PURPLE BIOTECH LTD. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/ppbt/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_ppbt_catalysts_20261116","title":"PPBT catalysts: PURPLE BIOTECH LTD. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/ppbt/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
